Developer docs
API playgroundTry for free, no card

Search company profiles

Holmusk

Full company profile

uuid0000hdl

Namestring
Holmusk
Legal namestring
Holmusk USA, Inc.
Websiteurl
holmusk.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Holmusk is a Singapore-headquartered (founded 2015) healthcare data and technology company that builds real-world evidence infrastructure for behavioral health and neuropsychiatry. Its flagship platform, NeuroBlu, combines a proprietary database of over 46 million de-identified patient lives drawn from longitudinal electronic health records across 30+ U.S. health systems and 50 states, with analytics software and clinical expertise services. The database is enriched using the company's proprietary BERT-based natural language processing models — the first developed specifically for behavioral health — which extract over 300 psychiatry-specific data labels (e.g., anhedonia, suicidality, CGI-S scores) from unstructured clinical notes. The company also operates MaST, a clinical decision support tool deployed across 8 UK NHS Mental Health Trusts for crisis risk prediction, and HolCare EHR+, a psychiatry-specific electronic health record with integrated measurement-based care.

Holmusk generates revenue primarily through subscription-based licensing of the NeuroBlu Database and NeuroBlu Analytics software to enterprise customers, supplemented by professional services where its clinical and data science teams guide study design and execution. Its primary customer segments are life sciences and biopharma companies (used by 5 of the top 15 biopharma with behavioral health pipelines for trial design, HEOR, and market access), payers and healthcare providers (care management and high-risk patient identification), academic and research institutions, and government/regulators. Distribution is sales-led with direct enterprise engagement, complemented by strategic partnerships — notably with Veradigm, Novartis, Optum Ventures, and Northwell Holdings — that simultaneously provide capital, data assets, and channel access into the healthcare ecosystem.

The company is privately held and has raised approximately $106M+ in venture funding across multiple rounds, including a $45M Series B led by Veradigm in January 2023. It maintains operating offices in Singapore (HQ), New York (U.S. HQ), London, and Basel, and has grown primarily through organic product expansion plus targeted acquisitions (MindLinc in 2016, Otsuka Health Solutions in 2021, and the MaST business). Holmusk's strategy is to consolidate fragmented behavioral health data into a research-grade real-world evidence platform that supports both drug development and clinical decision-making, with a recent push into neurology and Alzheimer's biomarker data extending its addressable market beyond pure psychiatry.

Short descriptiontext

Holmusk is a Singapore-based healthcare data and technology company that operates NeuroBlu, the largest real-world evidence platform for behavioral health and neuropsychiatry. It serves life sciences companies, payers, and providers with de-identified longitudinal patient data, NLP-enriched analytics, and clinical decision support tools.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
real-world evidence, behavioral health data, clinical decision support, electronic health records, natural language processing
Industry2 codes
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAEAB
Psychiatry & Medication Management Platforms
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
NAICS code2 codes
  • Research and Development in the Social Sciences and Humanities541720
  • Other Scientific and Technical Consulting Services541690
SIC code2 codes
  • Services-Misc Health & Allied Services, Nec8090
  • Services-Commercial Physical & Biological Research8731
Product category
Real-World Evidence Analytics Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1NeuroBlu Database Access
TypeSubscription Recurring
Description

Licensing of research-grade real-world evidence database to life sciences, biopharma, and biotech organizations for observational study design and evidence-generation workflows.

holmusk.com
2NeuroBlu Analytics Software
TypeSubscription Recurring
Description

User-friendly data analytics software with no-code analytics capabilities and pre-designed study templates. Provides self-service access to database insights.

holmusk.com
3Clinical Expertise Services
TypeProfessional Services
Description

Collaborative analysis services where Holmusk's team of clinical and data science experts guide customers through design and execution of end-to-end studies tailored to their organization's needs.

holmusk.com
4MaST Clinical Decision Support
TypeSubscription Recurring
Description

Clinical decision support tool (MaST) deployed to NHS Mental Health Trusts in the UK for crisis risk prediction and caseload management.

holmusk.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 7 records shown
1NeuroBlu
Description

Flagship real-world evidence platform for behavioral health providing database access, analytics software, and clinical expertise services

holmusk.com
+6 more records
Core offering1 text field

Holmusk builds and licenses the NeuroBlu real-world evidence platform for neuropsychiatry, comprising a de-identified longitudinal EHR database of 46+ million behavioral and neurological health patients, no-code analytics software, and clinical-expert study services. The company also offers MaST, a clinical decision support tool deployed across UK NHS Mental Health Trusts for crisis risk prediction, and HolCare EHR+, a psychiatry-specific electronic health record with integrated measurement-based care.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 72% of mental health crises identified as high risk in advance using MaST Risk-of-Crisis algorithm
+3 more records
Product overview1 text field

Holmusk offers a unified platform-plus-modules architecture centered on NeuroBlu, its flagship real-world evidence platform for neuropsychiatry. The core NeuroBlu platform comprises three integrated components: the NeuroBlu Database (a proprietary database of de-identified EHR data from 46+ million patients), NeuroBlu Analytics (no-code analytics software with pre-designed study templates), and NeuroBlu Services (expert consulting for study design and execution). The company also offers MaST, a clinical decision support tool with predictive crisis-risk algorithms deployed across UK NHS Mental Health Trusts, and HolCare EHR+, a psychiatry-specific EHR with integrated measurement-based care. MindLinc, an acquired psychiatry-specific EHR product, serves as a foundational data source for the NeuroBlu Database. The portfolio enables researchers to access longitudinal behavioral health data, conduct observational studies, and generate real-world evidence for drug development and clinical care improvement.

Product and service6 records
1NeuroBlu Database
CategoryReal-world evidence database
Description

The industry's largest real-world evidence database for behavioral health containing de-identified EHR data from over 46 million patients across 50 U.S. states with 20+ years of longitudinal data spanning inpatient and outpatient sites. Licensed to life sciences, biopharma, and biotech organizations for observational study design and evidence-generation workflows.

2NeuroBlu Analytics
CategoryAnalytics software
Description

User-friendly data analytics software with no-code analytics capabilities and pre-designed study templates that enables researchers to access insights from the NeuroBlu Database, independently explore the data, and build their own projects.

3NeuroBlu Services
CategoryProfessional services
Description

Clinical and data science expert services that collaborate with clients to design and execute end-to-end studies tailored to their organization's needs within the NeuroBlu platform.

4MaST (Management and Supervision Tool)
CategoryClinical decision support software
Description

Clinical decision support tool used in UK NHS Mental Health Trusts that leverages data visualization and predictive analytics via a Risk-of-Crisis algorithm to prioritize individuals at risk of mental health crisis and improve caseload management. Implemented across eight NHS Mental Health Trusts.

5HolCare EHR+
CategoryElectronic health record software
Description

Psychiatry-specific electronic health record platform with fully integrated measurement-based care designed to help make data capture easier and more complete for behavioral health clinicians.

6MindLinc
CategoryElectronic health record software
Description

Psychiatry-specific EHR/database product originally developed separately and later acquired; serves as a foundation for the NeuroBlu Database with most patient records containing Clinical Global Impressions Scale (CGI-S) measures.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-10-02
Description

Holmusk and Veradigm announced a new phase of strategic collaboration to enhance veterinary health outcomes using real-world data. The collaboration will expand Holmusk's NeuroBlu Database with millions of behavioral health patients' data from Veradigm, aiming to improve research and evidence generation in behavioral health.

2NHS Mental Health Trusts
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with NHS Mental Health Trusts in the UK for deployment of MaST (Management and Supervision Tool) clinical decision support system. Currently implemented across 8 NHS Mental Health Trusts as part of community mental health transformation initiative.

holmusk.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnerships with academic medical institutions for expanding the NeuroBlu Database and adding new behavioral health assessments and scales.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ConcertAI is a real-world evidence and AI platform serving life sciences and providers, with deep therapeutic-area focus. It competes head-to-head with Holmusk for biopharma RWE contracts, including in oncology and emerging specialty areas, and has raised substantially more capital.

TypeDirect peer
Description

Aetion provides an RWE analytics platform (Aetion Evidence Platform) used by biopharma and regulators to evaluate treatment effectiveness from real-world data. It directly competes with NeuroBlu Analytics for life-sciences RWE budget, especially for regulatory-grade submissions.

3Tempus Labs
TypeDirect peer
Description

Tempus combines molecular and clinical real-world data with AI analytics to support precision medicine, primarily oncology but expanding into neuropsychiatry and neurology. It overlaps with Holmusk's combination of large-scale clinical data and AI analytics for life-sciences research.

TypeDirect peer
Description

Komodo Health operates a large healthcare data map and analytics platform for life sciences, payers, and providers, with broad therapeutic coverage. It is a direct comparable in the RWE infrastructure layer, competing for similar biopharma and payer contracts as Holmusk.

TypeBroad incumbent
Description

Flatiron Health (acquired by Roche) is a leading oncology-focused RWE platform serving biopharma with de-identified EHR data and analytics. While primarily oncology, it sets the standard for specialty RWE platforms and competes for similar customer mindshare and partnerships Holmusk targets.

TypeBroad incumbent
Description

IQVIA is the largest global clinical and real-world evidence vendor serving biopharma across all therapeutic areas. As a broad incumbent with massive data assets, it competes with Holmusk for life-sciences RWE budgets and could replicate or acquire specialty behavioral health RWE capabilities.

TypeEmerging player
Description

Datavant focuses on health data connectivity and de-identification, enabling privacy-preserving linking of clinical datasets. Its ecosystem approach overlaps with Holmusk's data-partnership model and competes for the same underlying health-system data partnerships.

8Mendel
TypeEmerging player
Description

Mendel applies NLP to unstructured clinical text to make EHR data research-ready for life sciences. It competes directly with Holmusk's NLP enrichment layer as a technology alternative for transforming clinical notes into research-grade variables.

TypeOthers
Description

Veradigm is both Holmusk's lead investor and data partner, providing EHR-sourced patient cohorts that feed the NeuroBlu Database. While not a direct competitor, the relationship is strategic and creates a coupled ecosystem dynamic unique among Holmusk's peer set.

TypeEmerging player
Description

Eleos Health provides AI-powered clinical documentation and decision support for behavioral health providers. It competes with Holmusk's MaST offering in the behavioral health clinical decision-support market, although from a documentation/capture angle rather than data aggregation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Holmusk

Real-World Evidence Analytics Softwareholmusk.com

Holmusk is a Singapore-based healthcare data and technology company that operates NeuroBlu, the largest real-world evidence platform for behavioral health and neuropsychiatry. It serves life sciences companies, payers, and providers with de-identified longitudinal patient data, NLP-enriched analytics, and clinical decision support tools.

What Holmusk does

Holmusk is a Singapore-headquartered (founded 2015) healthcare data and technology company that builds real-world evidence infrastructure for behavioral health and neuropsychiatry. Its flagship platform, NeuroBlu, combines a proprietary database of over 46 million de-identified patient lives drawn from longitudinal electronic health records across 30+ U.S. health systems and 50 states, with analytics software and clinical expertise services. The database is enriched using the company's proprietary BERT-based natural language processing models — the first developed specifically for behavioral health — which extract over 300 psychiatry-specific data labels (e.g., anhedonia, suicidality, CGI-S scores) from unstructured clinical notes. The company also operates MaST, a clinical decision support tool deployed across 8 UK NHS Mental Health Trusts for crisis risk prediction, and HolCare EHR+, a psychiatry-specific electronic health record with integrated measurement-based care.

Holmusk generates revenue primarily through subscription-based licensing of the NeuroBlu Database and NeuroBlu Analytics software to enterprise customers, supplemented by professional services where its clinical and data science teams guide study design and execution. Its primary customer segments are life sciences and biopharma companies (used by 5 of the top 15 biopharma with behavioral health pipelines for trial design, HEOR, and market access), payers and healthcare providers (care management and high-risk patient identification), academic and research institutions, and government/regulators. Distribution is sales-led with direct enterprise engagement, complemented by strategic partnerships — notably with Veradigm, Novartis, Optum Ventures, and Northwell Holdings — that simultaneously provide capital, data assets, and channel access into the healthcare ecosystem.

The company is privately held and has raised approximately $106M+ in venture funding across multiple rounds, including a $45M Series B led by Veradigm in January 2023. It maintains operating offices in Singapore (HQ), New York (U.S. HQ), London, and Basel, and has grown primarily through organic product expansion plus targeted acquisitions (MindLinc in 2016, Otsuka Health Solutions in 2021, and the MaST business). Holmusk's strategy is to consolidate fragmented behavioral health data into a research-grade real-world evidence platform that supports both drug development and clinical decision-making, with a recent push into neurology and Alzheimer's biomarker data extending its addressable market beyond pure psychiatry.

Holmusk firmographics

Firmographics
Name
Holmusk
Legal name
Holmusk USA, Inc.
Website
https://holmusk.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Holmusk is a Singapore-based healthcare data and technology company that operates NeuroBlu, the largest real-world evidence platform for behavioral health and neuropsychiatry. It serves life sciences companies, payers, and providers with de-identified longitudinal patient data, NLP-enriched analytics, and clinical decision support tools.
Ownership category
akta.pro rank

Holmusk industry classification

Industry
Product category
Real-World Evidence Analytics Software
NAICS
Research and Development in the Social Sciences and Humanities (541720), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Misc Health & Allied Services, Nec (8090), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAEAB
Psychiatry & Medication Management Platforms
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms

Keywords

  • Real-world evidence
  • Behavioral health data
  • Clinical decision support
  • Electronic health records
  • Natural language processing

Where Holmusk is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Holmusk business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. NeuroBlu Database Access: Licensing of research-grade real-world evidence database to life sciences, biopharma, and biotech organizations for observational study design and evidence-generation workflows.
  2. NeuroBlu Analytics Software: User-friendly data analytics software with no-code analytics capabilities and pre-designed study templates. Provides self-service access to database insights.
  3. Clinical Expertise Services: Collaborative analysis services where Holmusk's team of clinical and data science experts guide customers through design and execution of end-to-end studies tailored to their organization's needs.
  4. MaST Clinical Decision Support: Clinical decision support tool (MaST) deployed to NHS Mental Health Trusts in the UK for crisis risk prediction and caseload management.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Holmusk product offering

Product offering

Core offering

Holmusk builds and licenses the NeuroBlu real-world evidence platform for neuropsychiatry, comprising a de-identified longitudinal EHR database of 46+ million behavioral and neurological health patients, no-code analytics software, and clinical-expert study services. The company also offers MaST, a clinical decision support tool deployed across UK NHS Mental Health Trusts for crisis risk prediction, and HolCare EHR+, a psychiatry-specific electronic health record with integrated measurement-based care.

Product overview

Holmusk offers a unified platform-plus-modules architecture centered on NeuroBlu, its flagship real-world evidence platform for neuropsychiatry. The core NeuroBlu platform comprises three integrated components: the NeuroBlu Database (a proprietary database of de-identified EHR data from 46+ million patients), NeuroBlu Analytics (no-code analytics software with pre-designed study templates), and NeuroBlu Services (expert consulting for study design and execution). The company also offers MaST, a clinical decision support tool with predictive crisis-risk algorithms deployed across UK NHS Mental Health Trusts, and HolCare EHR+, a psychiatry-specific EHR with integrated measurement-based care. MindLinc, an acquired psychiatry-specific EHR product, serves as a foundational data source for the NeuroBlu Database. The portfolio enables researchers to access longitudinal behavioral health data, conduct observational studies, and generate real-world evidence for drug development and clinical care improvement.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroBlu: Flagship real-world evidence platform for behavioral health providing database access, analytics software, and clinical expertise services
  • NeuroBlu Database
  • NeuroBlu Analytics
  • MaST
  • MindLinc
  • HolCare EHR+
  • The Hol Picture

Products and services

  • NeuroBlu Database The industry's largest real-world evidence database for behavioral health containing de-identified EHR data from over 46 million patients across 50 U.S. states with 20+ years of longitudinal data spanning inpatient and outpatient sites. Licensed to life sciences, biopharma, and biotech organizations for observational study design and evidence-generation workflows.
  • NeuroBlu Analytics User-friendly data analytics software with no-code analytics capabilities and pre-designed study templates that enables researchers to access insights from the NeuroBlu Database, independently explore the data, and build their own projects.
  • NeuroBlu Services Clinical and data science expert services that collaborate with clients to design and execute end-to-end studies tailored to their organization's needs within the NeuroBlu platform.
  • MaST (Management and Supervision Tool) Clinical decision support tool used in UK NHS Mental Health Trusts that leverages data visualization and predictive analytics via a Risk-of-Crisis algorithm to prioritize individuals at risk of mental health crisis and improve caseload management. Implemented across eight NHS Mental Health Trusts.
  • HolCare EHR+ Psychiatry-specific electronic health record platform with fully integrated measurement-based care designed to help make data capture easier and more complete for behavioral health clinicians.
  • MindLinc Psychiatry-specific EHR/database product originally developed separately and later acquired; serves as a foundation for the NeuroBlu Database with most patient records containing Clinical Global Impressions Scale (CGI-S) measures.

Quantifiable outcome

  • 72% of mental health crises identified as high risk in advance using MaST Risk-of-Crisis algorithm
  • +3 more outcomes

Companies that use Holmusk

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Holmusk technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Holmusk partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered strategic, core and minor.

  • VeradigmstrategicStrategic or Co-development Partner · 2 October 2023Holmusk and Veradigm announced a new phase of strategic collaboration to enhance veterinary health outcomes using real-world data. The collaboration will expand Holmusk's NeuroBlu Database with millions of behavioral health patients' data from Veradigm, aiming to improve research and evidence generation in behavioral health.
  • NHS Mental Health TrustscoreStrategic or Co-development PartnerPartnership with NHS Mental Health Trusts in the UK for deployment of MaST (Management and Supervision Tool) clinical decision support system. Currently implemented across 8 NHS Mental Health Trusts as part of community mental health transformation initiative.
  • Academic Medical InstitutionsminorStrategic or Co-development PartnerPartnerships with academic medical institutions for expanding the NeuroBlu Database and adding new behavioral health assessments and scales.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Holmusk competitors and assessment

Company assessment

Direct peers

  • ConcertAI: ConcertAI is a real-world evidence and AI platform serving life sciences and providers, with deep therapeutic-area focus. It competes head-to-head with Holmusk for biopharma RWE contracts, including in oncology and emerging specialty areas, and has raised substantially more capital.
  • Aetion: Aetion provides an RWE analytics platform (Aetion Evidence Platform) used by biopharma and regulators to evaluate treatment effectiveness from real-world data. It directly competes with NeuroBlu Analytics for life-sciences RWE budget, especially for regulatory-grade submissions.
  • Tempus Labs: Tempus combines molecular and clinical real-world data with AI analytics to support precision medicine, primarily oncology but expanding into neuropsychiatry and neurology. It overlaps with Holmusk's combination of large-scale clinical data and AI analytics for life-sciences research.
  • Komodo Health: Komodo Health operates a large healthcare data map and analytics platform for life sciences, payers, and providers, with broad therapeutic coverage. It is a direct comparable in the RWE infrastructure layer, competing for similar biopharma and payer contracts as Holmusk.

Broad incumbents

  • Flatiron Health: Flatiron Health (acquired by Roche) is a leading oncology-focused RWE platform serving biopharma with de-identified EHR data and analytics. While primarily oncology, it sets the standard for specialty RWE platforms and competes for similar customer mindshare and partnerships Holmusk targets.
  • IQVIA: IQVIA is the largest global clinical and real-world evidence vendor serving biopharma across all therapeutic areas. As a broad incumbent with massive data assets, it competes with Holmusk for life-sciences RWE budgets and could replicate or acquire specialty behavioral health RWE capabilities.

Emerging players

  • Datavant: Datavant focuses on health data connectivity and de-identification, enabling privacy-preserving linking of clinical datasets. Its ecosystem approach overlaps with Holmusk's data-partnership model and competes for the same underlying health-system data partnerships.
  • Mendel: Mendel applies NLP to unstructured clinical text to make EHR data research-ready for life sciences. It competes directly with Holmusk's NLP enrichment layer as a technology alternative for transforming clinical notes into research-grade variables.
  • Eleos Health: Eleos Health provides AI-powered clinical documentation and decision support for behavioral health providers. It competes with Holmusk's MaST offering in the behavioral health clinical decision-support market, although from a documentation/capture angle rather than data aggregation.

Others

  • Veradigm (Allscripts spinoff): Veradigm is both Holmusk's lead investor and data partner, providing EHR-sourced patient cohorts that feed the NeuroBlu Database. While not a direct competitor, the relationship is strategic and creates a coupled ecosystem dynamic unique among Holmusk's peer set.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Holmusk social profiles

Digital presence

Holmusk financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Holmusk leadership team

Management profile

Number of profiles

Profiles13 records

Holmusk subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Holmusk funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Holmusk M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Holmusk

What does Holmusk do?

Holmusk builds and licenses the NeuroBlu real-world evidence platform for neuropsychiatry, comprising a de-identified longitudinal EHR database of 46+ million behavioral and neurological health patients, no-code analytics software, and clinical-expert study services. The company also offers MaST, a clinical decision support tool deployed across UK NHS Mental Health Trusts for crisis risk prediction, and HolCare EHR+, a psychiatry-specific electronic health record with integrated measurement-based care.

Is Holmusk a public or private company?

Holmusk is a private company. It is classified as venture growth investor backed and is currently operating.

When was Holmusk founded?

Holmusk was founded in 2015. It employs 51 to 100 people.

Where is Holmusk based?

Holmusk is headquartered in New York, United States, in the North America region.

How does Holmusk make money?

Four revenue lines are on record. NeuroBlu Database Access are the primary driver. The others are neuroBlu Analytics Software, clinical Expertise Services and maST Clinical Decision Support.

Who are Holmusk's main competitors?

Direct peers on record are ConcertAI, Aetion, Tempus Labs and Komodo Health. Broad incumbents are Flatiron Health and IQVIA. Emerging players are Datavant, Mendel and Eleos Health. Veradigm (Allscripts spinoff) is listed as an others.

Does Holmusk have an API?

No public API is recorded for Holmusk.

What industry is Holmusk in?

Holmusk's product category is Real-World Evidence Analytics Software. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HLALAEAB, Psychiatry & Medication Management Platforms. Its NAICS code is 541720 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Weforum5 ways Singapore is building trust in AI for better patient careSingapore is implementing a responsible AI framework in healthcare through regulatory sandboxes, hospital pilots, and inclusive dataset initiatives to ensure patient safety and reduce bias. Key projects include Holmusk’s mental health tool testing and Ng Teng Fong General Hospital’s Project ENTenna, which uses AI to improve discharge rates and medication adherence. The government also fosters cross-sector collaboration with entities like A*STAR and SingHealth while sharing governance standards regionally via the ASEAN AI Health Working Group.PR NewswireHolmusk Expands NeuroBlu to 46 Million Patients, Adding Depth and Biomarker Data Across Neurology and Behavioral HealthHolmusk announced a major expansion of its NeuroBlu platform to over 46 million de-identified patient lives, adding two top-ranked neurological health systems, structured Alzheimer's disease biomarker data, and validated clinical outcomes measures across neurological disease areas. The 26R2 release includes data on 19 million patients (41% of the platform) carrying both neurological and behavioral health diagnoses within the same longitudinal record. NeuroBlu 26R2 is available now to life sciences, biopharma, and biotech organizations for observational study design and evidence-generation workflows.PR NewswireHolmusk Expands NeuroBlu to 46 Million Patients, Adding Depth and Biomarker Data Across Neurology and Behavioral HealthHolmusk announced a major expansion of its NeuroBlu platform, growing to over 46 million de-identified patient lives from longitudinal EHR data—an increase of more than 5 million—with the addition of two top-ranked neurological health systems and structured biomarker data for Alzheimer's disease research. The platform now provides validated outcomes measures across neurological and behavioral health conditions, with over 19 million patient lives carrying both neurological and behavioral health diagnoses within the same longitudinal record. NeuroBlu 26R2 is available to life sciences, biopharma, and biotech organizations seeking research-grade real-world evidence.PR Newswire APACHolmusk Expands NeuroBlu to 46 Million Patients, Adding Depth and Biomarker Data Across Neurology and Behavioral HealthHolmusk expanded NeuroBlu to over 46 million de-identified patient lives, adding 5 million and two top-ranked neurological health systems. The release includes structured Alzheimer's biomarker data and validated outcomes measures across neurological and behavioral health conditions.GlobeNewswireMental Health Technology Market Forecast Report 2025-2030: AI-Driven Mental Health Solutions Revolutionize 24/7 Care AccessibilityResearchAndMarkets published a market research report projecting the global mental health technology market to grow from USD 15.22 billion in 2024 to USD 30.98 billion by 2030, representing a CAGR of 12.58%. The report highlights AI-driven solutions, teletherapy, and mobile apps as key growth drivers, with North America commanding over 50% market share and the Asia-Pacific region recording the fastest growth at 13.18% CAGR. Notable recent developments include Iris Telehealth's strategic partnership with Holmusk in June 2025 and Lyra Health's launch of the AI-powered Lyra Empower platform in April 2025, while regulatory challenges around data privacy and inconsistent frameworks remain sector headwinds.PR NewswireIris Telehealth and Holmusk Announce Strategic Partnership to Advance Data-Driven Mental Health CareIris Telehealth and Holmusk announced a strategic partnership integrating Holmusk's NeuroBlu AI platform with Iris Insights to provide localized behavioral health data. The collaboration aims to identify at-risk patients through risk stratification and apply AI and NLP to predict patient risk. It targets healthcare organizations facing clinician shortages and pressure to demonstrate outcomes.PR NewswireHolmusk and Veradigm Reach New Data Enrichment Milestone in Strategic CollaborationHolmusk and Veradigm announced they have reached a new data enrichment milestone in their strategic collaboration, transforming semi-structured EHR data into analyzable structured data to assess mental health disorder progression. The enriched data, covering millions of patient profiles with high-density psychometric scales, is now available in NeuroBlu Data, the largest NLP-enriched real-world dataset for mental health. The companies, with Veradigm having led Holmusk's 2023 Series B funding round, will continue leveraging their partnership to optimize data availability and standardization for real-world evidence generation in mental health.citybizHolmusk Appoints Eze Abosi as Chief Growth OfficerHolmusk, a behavioral health real-world evidence company, has appointed Eze Abosi as its new Chief Growth Officer to lead the organization’s commercial team. Abosi brings nearly two decades of experience in life sciences and biopharma commercialization, with previous leadership roles at Optum Life Sciences, IQVIA, and Decision Resources Group. In this position, he will drive revenue growth and expand collaborations with payors and providers to promote real-world data solutions in mental healthcare.SecSEC FORM DHolmusk Corp filed a Form D with the U.S. Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing indicates a total offering amount of $29,999,978, which was fully sold as of the first sale date in September 2023. This regulatory submission serves as a formal notice of the private equity raise to federal authorities.HIT ConsultantVeradigm Invests $30M in Behavioral Health Co. HolmuskVeradigm announced a $30M strategic investment in Holmusk, a behavioral health real-world evidence company. The investment will add cohorts of millions of behavioral health patients and de-identified clinical data from Veradigm to Holmusk's NeuroBlu Database, expanding its research capabilities.